The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

DeFronzo, Ralph A., Hissa, Miguel N., Garber, Alan J., Luiz Gross, Jorge, Yuyan Duan, Raina, Ravichandran, Shoba, Chen, Roland S., for the Saxagliptin 014 Study Group·2009·Diabetes Care
DOI 10.2337/dc08-1984

Cited by (415)

Items 301–400 of 415

  1. Importancia de la variabilidad del control glucémico diario en la consecución de los objetivos de control en la diabetes mellitus tipo 2: papel de los inhibidores de la dipeptidil peptidasa 4
    Francisco Javier Ampudia‐Blasco, Antonio Ceriello · 2010 · Medicina Clínica
  2. Hypoglycaemia in patients with type 2 diabetes: minimising the risk
    Miles Fisher · 2010 · The British Journal of Diabetes
  3. Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?
    Thaddeus John Bell, Eugene E. Wright · 2010 · Journal of the National Medical Association
  4. Exploration of the DPP-4 inhibitors with a focus on saxagliptin
    Jay H. Shubrook, Randall A. Colucci, Frank Schwartz · 2009 · Expert Opinion on Pharmacotherapy
  5. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes
    Jean–François Gautier, J.-P. Sauvanet · 2011 · Annales d Endocrinologie
  6. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients
    Jianke Li, Kirsti Klemm, A. Marie O'Farrell, Hans‐Peter Guler, Julie M. Cherrington, Sherwyn Leon Schwartz, Teresa Boyea · 2010 · Current Medical Research and Opinion
  7. Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
    Marc Rendell, Steven G. Chrysant · 2011 · Postgraduate Medicine
  8. Review: Saxagliptin: a review
    Marc Evans · 2010 · The British Journal of Diabetes
  9. Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis
    Lingyu He, Shu Liu, Chun Shan, Yingmei Tu, Zhengqing Li, Xiaohua Douglas Zhang · 2016 · BMC Pharmacology and Toxicology
  10. Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement
    James Flory, Alvin I. Mushlin · 2014 · Journal of Clinical Epidemiology
  11. Overcoming challenges in Type 2 diabetes management to improve patient outcomes
    Marie T. Brown, Derek LeRoith · 2010 · Expert Review of Endocrinology & Metabolism
  12. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates
    Agata Schubert, Anders T. Buchholt, Antoine C. El Khoury, Ahmed Kamal, V. Taieb · 2017 · Current Medical Research and Opinion
  13. Neue Arzneimittel 2009
    Uwe Fricke, U. Schwabe · 2010 · Springer eBooks
  14. Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials
    W. James Cook, Gianmaria Minervini, Brian S. Bryzinski, Boaz Hirshberg · 2014 · Postgraduate Medicine
  15. Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia
    Matthew L. Mintz, Gianmaria Minervini · 2014 · Current Medical Research and Opinion
  16. Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes
    Ayşe Nur Torun, Derun Taner Ertuğrul · 2015 · InTech eBooks
  17. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
    Shira Perl, William Cook, Cheryl Wei, Nayyar Iqbal, Boaz Hirshberg · 2016 · Diabetes Therapy
  18. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
    Alexander Kühn, Jean Park, Adline Ghazi, Vanita R. Aroda · 2017 · Current Cardiology Reports
  19. Knowledge about leprosy among leprosy patients.
    V Raj, B Garg, Shyam Lal · 1981 · PubMed
  20. Oral Agents for Type-2 Diabetes
    Ronald A. Codario · 2010 · Humana Press eBooks
  21. Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies
    Sherwyn Leon Schwartz · 2011 · Annals of Medicine
  22. Incretin therapy for type 2 diabetes mellitus
    D. Klonoff · 2010 · Advances in Therapy
  23. Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data
    Suellen M. Curkendall, Bin Zhang, Gregory M. Lenhart, Erin Thomson, Kelly F. Bell · 2014 · Expert Review of Endocrinology & Metabolism
  24. Dapagliflozin combination therapy in type 2 diabetes mellitus
    Tamer G. Yacoub · 2015 · Postgraduate Medicine
  25. Type 2 Diabetes and Developmental Origin of Non-Alcohol Fatty Liver Disease and Future Directions of Treatment
    Hassan I. El‐Sayyad, El Shahary · 2016 · Clinical and Experimental Pharmacology
  26. Incretin‐based therapies
    Michael Albrecht Nauck, Juris Jendrik Meier · 2015
  27. SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS
    Anupam Jamwal · 2020 · International Journal of Pharmacy and Pharmaceutical Sciences
  28. Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
    Lixin Guo, Fengsheng Tian, Li Liu, Mingwei Chen, Chengxia Jiang, Shuangqing Li, Cong Liu, Yawei Zhang, Jie Qin, Dongni Yu et al. · 2024 · Diabetes Obesity and Metabolism
  29. Putting medications where they belong: Practical advice for managing type 2 diabetes in clinical practice
    Jeff Unger, Debbie Hinnen, Barbara Schreiner, Chris Parkin · 2012 · Journal of the American Academy of Nurse Practitioners
  30. Advantages and Pitfalls of Antihyperglycemic Combination Pills as First-Line Therapy in the Management of Type 2 Diabetes
    Ariana Mooradian, Joe M. Chehade, Arshag D. Mooradian · 2015 · American Journal of Therapeutics
  31. Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis
    Jin Yang, Qing Tian, Yuexin Tang, Arvind Kumar Shah, Ruya Zhang, Guojuan Chen, Ye Zhang, Swapnil N. Rajpathak, Tianpei Hong · 2020 · Diabetes Therapy
  32. Adverse drug reactions monitoring of newer oral hypoglycemic drugs in a tertiary care hospital of North India: a prospective study
    Shephali Singh, Nilam Nigam, Shalini Gupta, Shravan Kumar · 2017 · International Journal of Basic & Clinical Pharmacology
  33. Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents
    Ronald Goldenberg · 2011 · Canadian Journal of Diabetes
  34. Comparison of DPP-4 Inhibitors
    Nam Hoon Kim, Sin Gon Kim · 2013 · Journal of Korean Diabetes
  35. How to Obtain Appropriate Type 2 Diabetes Control in the First 180 Days of Treatment Initiation
    Louis Kuritzky, Benjamin J Epstein, Frank Lavernia · 2010 · Postgraduate Medicine
  36. Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes
    Amir Hanna, Vincent C. Woo, Jean‐François Yale, Elaine M. Cooke · 2012 · Canadian Journal of Diabetes
  37. META-ANALYSIS OF THE CARDIOVASCULAR OUTCOMES WITH DIPEPTIDYL PEPTIDASE 4 INHIBITORS: VALIDATION OF THE CURRENT FDA MANDATE
    Shikhar Agarwal, Akhil Parashar, Venu Menon · 2014 · Journal of the American College of Cardiology
  38. Traitement du diabète en dehors de l'insuline
    Jean‐Frédéric Blickle · 2011 · EMC - Endocrinologie - Nutrition
  39. Comment on “Enhanced Recovery in Patients With Diabetes: Is It Time for a Moratorium on Use of Preoperative Carbohydrate Beverages?” I Agree With Your Perspective
    Nathaniel P. Morin · 2019 · Annals of Surgery
  40. Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events
    Marc‐Olivier Pilon, Simon de Denus, Géraldine Asselin, Marc‐André Legault, Hervira Brenda Ngongang Kwandjang, Amina Barhdadi, Louis‐Philippe Lemieux Perreault, Diane Valois, Ian Mongrain, Carolina Haefliger et al. · 2026 · BMC Medical Genomics
  41. Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
    Molly G. Minze, Mary S. Klein, Brian T. Terrell · 2013 · Clinical Medicine Insights Endocrinology and Diabetes
  42. An update on the ‘gliptins’
    2016 · Drug and Therapeutics Bulletin
  43. Recent Diabetes Issues Affecting the Primary Care Clinician
    Karen R Sando, Jose Barboza, Crystal D. Willis, James Taylor · 2011 · Southern Medical Journal
  44. Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy
    Brian S. Bryzinski, Elsie Allen, W. James Cook, Boaz Hirshberg · 2014 · Journal of Diabetes and its Complications
  45. New Drugs Approved in 2009
    Erin L. Sears, Sarah Brooks · 2010 · Baylor University Medical Center Proceedings
  46. Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge
    Bruce W. Bode, Alpesh Amin · 2009 · Hospital Practice
  47. Self-Monitoring of Blood Glucose in Glucagon-Like Peptide-1–Based Treatment Approaches
    Oliver Schnell, Anne-Marie Felton · 2013 · Diabetes Spectrum
  48. Saxagliptin plus metformin combination therapy
    André Jacques Scheen · 2012 · Expert Review of Endocrinology & Metabolism
  49. The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
    Beverley Balkau, Bernard H. Charbonnel, Alfred Penfornis, N. Chraibi, Amir Lahouegue, Céline Faure, Florence Thomas‐Delecourt, B. Detournay · 2017 · Diabetes Therapy
  50. Value-Based Payments and Incentives to Improve Care: A Case Study of Patients with Type 2 Diabetes in Medicare Advantage
    Jesse A. Sussell, Katalin Bognar, Taylor Schwartz, Jason T. Shafrin, John J. Sheehan, Wade M Aubry, Dennis Patrick Scanlon · 2017 · Value in Health
  51. PVP/Clay/Vanadium Oxide Nanocomposites Development and Characterization for Potential Use as Controlled Drug Release Matrix in Diabetes’ Treatment
    Dario Barreto Reino de Almeida, Maria Inês Bruno Tavares · 2019 · Materials Sciences and Applications
  52. Saxagliptin (Onglyza) for Type 2 Diabetes
    2010 · Obstetrics and Gynecology
  53. Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes
    Michael Shawn McFarland, Meghan Brock, Casey Ryals · 2011 · Southern Medical Journal
  54. Träger: Bundesärztekammer Kassenärztliche Bundesvereinigung Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
    Nationale VersorgungsLeitlinie · 2011
  55. Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine
    Donald C. Simonson, Marcia A. Testa, Ella Ekholm, Maxwell Su, Tina Vilsbøll, Serge A Jabbour, Marcus Lind · 2024 · The Journal of Clinical Endocrinology & Metabolism
  56. Antidiabéticos orales y riesgo cardiovascular
    Serra Sansone, María del Pilar · 2012 · Redalyc (Universidad Autónoma del Estado de México)
  57. New and Future Medications for the Treatment of Type 2 Diabetes Mellitus
    Michael C. Mathers, Sommer D. Zarbock, Emily Sutton · 2013 · American Journal of Lifestyle Medicine
  58. Incretin-based Therapies for Type 2 Diabetes—Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
    Timothy Silleck Bailey · 2011 · US Endocrinology
  59. A GC–MS untargeted metabolomics analysis in the plasma and liver of rats lacking dipeptidyl-peptidase type IV enzyme activity
    Antonio Murgia, Pierluigi Caboni, Erika Cadoni, Monica Serra, Fabio Marongiu, Ezio Laconi · 2017 · Journal of Physiology and Biochemistry
  60. INCRETIN-BASED THERAPY
    Yoshio Fujitani · 2012 · Juntendō Igaku/Juntendo igaku
  61. Clinical assessment of saxagliptin therapy in diabetic patients with corpulence
    Feryal Hashim Rada · 2022 · GSC Biological and Pharmaceutical Sciences
  62. Actualización sobre la última familia de fármacos orales comercializados para el tratamiento de la diabetes tipo 2: los inhibidores de la DPP-4. Aportaciones respecto a las otras familias de antidiabéticos orales
    Fernando Álvarez Guisasola · 2010 · Atención Primaria
  63. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score
    Enzo Bonora, Brian S. Bryzinski, Boaz Hirshberg, W. Cook · 2015 · Nutrition Metabolism and Cardiovascular Diseases
  64. Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials
    Mikaela Sjöstrand, Gil Leibowitz · 2016 · Journal of Diabetes & Metabolism
  65. Saxagliptin: a guide to its use in type 2 diabetes mellitus
    K. Lyseng-Williamson, Lily P. H. Yang · 2014 · Drugs & therapy perspectives
  66. Gut Hormones and Metabolic Syndrome
    Salman Zahoor Bhat, Hyeong Kyu Park, Rexford S. Ahima · 2023 · Springer eBooks
  67. Incretin-based therapies and their future in Type 2 diabetes mellitus
    Travis E. Sonnett, Jennifer D. Robinson, Kurt A. Bowen · 2011 · Therapy
  68. Consensus ADA/EASD 2009 : l’algorithme pour le traitement médical du diabète de type 2 est utile !
    J.-P. Sauvanet · 2010 · Médecine des Maladies Métaboliques
  69. Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus
    K. Athanasia, Marina S., I. Stavros · 2011 · InTech eBooks
  70. Efectos del tratamiento oral con inhibidores de dipeptidilpeptidasa-4 y biguanidas sobre el metabolismo óseo
    María Laura Sbaraglini · 2014
  71. ANTIHYPERGLYCEMIC THERAPY FOR PATIENTS WITH DIABETES MELLITUS TYPE 2
    Е. Е. Томина · 2013 · DOAJ (DOAJ: Directory of Open Access Journals)
  72. Saxagliptina, un nuevo inhibidor de la DPP-4 en el tratamiento de la diabetes mellitus tipo 2: aspectos novedosos
    Pablo B. Pedrianes Martín, Pedro Luis de Pablos-Velasco · 2010 · Avances en Diabetología
  73. Incretin therapies for type 2 diabetes: what nurses need to know
    Brenda Capaldi · 2012 · Nurse Prescribing
  74. New therapies for the treatment of type 2 diabetes: an update
    Caroline Day · 2009 · European Diabetes Nursing
  75. GLP-1: ein neues Therapieprinzip für die Behandlung des Diabetes mellitus Typ 2
    Björn A. Menge, Juris Jendrik Meier, Wolfgang Ekkehard Schmidt · 2010 · Medizinische Klinik - Intensivmedizin und Notfallmedizin
  76. Dapagliflozin: a guide to its use in type 2 diabetes mellitus
    Mary Hines, K. Lyseng-Williamson, G. Plosker · 2012 · Drugs & therapy perspectives
  77. Extension of the group of incretin-targeted preparations: Saxagliptin – a new dipeptidyl peptidase-4 inhibitor
    Marina Vladimirovna Shestakova, Olga Yu. Sukhareva · 2010 · Problems of Endocrinology
  78. Comment on Gerich – DPP-4 inhibitors: What may be the clinical differentiators?
    Roland K. Chen, Peter Öhman, Mark Kirby · 2011 · Diabetes Research and Clinical Practice
  79. The Efficacy and Safety of Saxagliptin in Haemodialysis Patients
    Abdul Halim Abdul Gafor, Azrina Abdul Kadir, Rizna Abdul Cader, Rozita Mohd, Kong Wei Yen, Rohana Abdul Ghani, Shamsul Azhar Shah, Norella C. T. Kong · 2013 · Open Journal of Nephrology
  80. New pharmacological approaches to diabetes management
    Abdallah Al Eyadeh, Paul E Jennings · 2015 · Practice Nursing
  81. Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes
    2010 · Clinical Medicine Reviews in Vascular Health
  82. Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors
    Rameshwar Mahaseth · 2015 · Journal of Patan Academy of Health Sciences
  83. Dipeptidyl Peptidase‐4 Inhibitors
    Anthony H Barnett, Jenny Grice · 2011 · Wiley eBooks
  84. INCRETIN-BASED THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES
    Constantin Ionescu-Tirgoviste, Carol Davila, Rucsandra Dănciulescu Miulescu · 2010
  85. Clinical Use of Incretin-Based Therapy in Type 2 Diabetes Mellitus
    Mansur E. Shomali · 2011
  86. Diabetes in China 3 Early therapy for type 2 diabetes in China
    Wenying Yang, Guangdong Provincial Key · 2014
  87. Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus
    Sity Aishah Mansur · 2015 · UTHM Institutional Repository (Universiti Tun Hussein Onn Malaysia)
  88. Drug Profile—Saxagliptin, a Novel Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes
    Baptist Gallwitz · 2010 · touchREVIEWS in Endocrinology
  89. The Discovery of the Dipeptidyl Peptidase-4 (DPP4) Inhibitor Onglyza™: From Concept to Market
    Jeffrey A. Robl, Lawrence G. Hamann · 2010 · Royal Society of Chemistry eBooks
  90. The Role of Incretins in Insulin Secretion
    Marzieh Salehi · 2016 · Springer eBooks
  91. Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil
    Bristol-Myers Squibb · 2012
  92. Factors associated with physician prescribing behavior of dipeptidyl peptidase-4 inhibitors for type 2 diabetes in the US outpatient population
    Xiaojing Ma, Chanhyun Park, Hsien‐Chang Lin, Sweta Andrews, Jongwha Chang · 2017 · Journal of Hospital Administration
  93. Pharmacology of Dipeptidyl Peptidase-4 Inhibitors and Differences
    Roberta Baetta, Alberto Corsini · 2011
  94. Diabète de type2: antidiabétiques oraux
    L. Monnier, Cl. Colette · 2017
  95. Diabète de type2: antidiabétiques oraux avec risque hypoglycémique
    Louis Monnier, Cl. Colette · 2017
  96. Add-on saxagliptin improves glycemic status among uncontrolled type 2 diabetes mellitus
    Butungeshwar Pradhan, Chakradhar Majhi, Madhusmita Sahu · 2018 · International Journal of Research in Medical Sciences
  97. [Zonal variability and seasonal changes of the content of glycogen and glucose in the Mytilus mantle].
    C A Crespo, J Espinosa · 1989 · PubMed
  98. Thérapeutique des désordres glycémiques
    2014 · Elsevier eBooks
  99. SAXAGLIPTIN: A SYSTEMATIC REVIEW ON ITS PHARMACOLOGICAL POTENTIAL AND ANALYTICAL ASPECTS
    Badruddeen Badruddeen · 2020 · International Journal of Medical & Pharmaceutical Sciences
  100. Study the effect of Dipeptidyl Peptidase 4 Inhibitors as an Antidiabetic in Type 2 Diabetes Mellitus (T2DM)
    2021 · American Journal of PharmTech Research